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Cervical smears prepared around the time of menses have been linked to unsatisfactory specimens and false negative results;
however, it is unclear whether liquid-based cytology is similarly affected and data relating date of last menstrual period (LMP) to
human papillomavirus (HPV) DNA testing are conflicting. Accordingly, we evaluated liquid-based cytology and HPV test results using
Hybrid Capture 2 and PCR by LMP (days 0–10; 11–21; 22–28). We studied 5060 participants in ALTS, the Atypical Squamous Cells
of Undetermined Significance (ASCUS) Low Grade Squamous Intraepithelial Lesion (LSIL) Triage Study. On average, women had 3.4
examinations (median 4, range 1–5) during a 2-year period of observation permitting an examination of intra-individual variation in
cytology and HPV by LMP. Although uncommon, unsatisfactory cytology specimens were most likely on days 0–10. For satisfactory
specimens, the frequency with which cytologic categories were reported varied by time since LMP, although differences were modest
and did not affect the chance of abnormal cytology or its severity among women diagnosed with CIN2þ. The frequency of positive
HC2 tests did not vary with date of LMP. Among HPV infected women, independent of eventual diagnosis and the number of viral
genotypes present, mid-cycle specimens yielded the highest frequency of LSIL cytologic interpretations and the highest HPV load;
however, the magnitude of these effects were small. Intraindividual correlations of cytology or HPV by LMP were generally weak. We
conclude that mid-cycle specimens yield slightly higher HPV DNA loads and slightly increased LSIL interpretations, but the clinical
impact is marginal. Standardizing collection times would slightly improve interpretation of trends in HPV load. Finally, these data are
consistent with the view that the biological properties of the HPV-infected cervix vary with the date of the LMP.
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Important goals of cervical cancer research include improving
detection of precancerous lesions and reducing equivocal results
by employing better collection, preparation, and testing methods
(Baldwin et al, 2003). Previous analyses of cytology results
obtained with conventional smears have documented that
suboptimal specimens result in increased reporting of false
negative and equivocal results (Gay et al, 1985; Mitchell et al,
1990; Pairwuti, 1991; Henry and Wadehra, 1996; Ransdell et al,
1997; Mintzer et al, 1999; Boon et al, 2003; Nygard et al, 2004).
Although many factors affect the quality of cervical cellular
specimens, the time of sampling with respect to a woman’s last
menstrual period (LMP) has demonstrated importance.
Historically, clinicians have recognized that cytologic samples
collected on days of active menstruation are typically bloody and
often yield smears that are hypocellular, obscured, and lack
endocervical cells (Vooijs et al, 1987). Furthermore, data
demonstrating that unsatisfactory cytology specimens are asso-
ciated with a higher than expected frequency of cervical
intraepithelial neoplasia (CIN) and carcinoma (Ransdell et al,
1997; Nygard et al, 2004) in later follow-up, suggest that that these
specimens may be linked to false negative results. However, efforts
to coordinate return visits to re-screen women with unsatisfactory
cytology often fail (McGarahan and Smith-McCune, 2005), and
presumably, deferring screening for women who present near the
time of menses would present similar problems. Given this
dilemma, it is important to determine whether the advantages of
liquid-based cytology methods, such as increased cellular recovery
and reduction of obscuring by blood (Bernstein et al, 2001),
eliminate the association between the performance of cytology and
LMP that has been demonstrated for smears.
Similarly, the implementation of concurrent human papilloma-
virus (HPV) DNA and cytologic testing in some settings highlights
the need to clarify inconsistencies in reported analyses assessing
the performance of HPV testing in relation to LMP (Schneider
et al, 1992; Fairley et al, 1994; Wheeler et al, 1996; Van Ham et al,
2002; Harper et al, 2003). Accordingly, we analyzed data for
cytology and HPV DNA testing by LMP collected in the National
Cancer Institute sponsored ASCUS LSIL Triage Study (ALTS).
MATERIALS AND METHODS
Subject selection
ASCUS LSIL Triage Study was a randomized clinical trial that
enrolled subjects with community cytologic interpretations of
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sASCUS (n¼3488) or LSIL (n¼1572) at four clinical centres in the
US (Schiffman and Adrianza, 2000). The study was approved by
responsible review boards at the National Cancer Institute and
participating institutions.
Clinical procedures and pathology review
At enrollment, eligible subjects were interviewed regarding risk
factors for cervical cancer and then underwent a pelvic examina-
tion, followed by collection of two cervical samples. The first
specimen, collected with a Papettet broom (Wallach Surgical,
Orange, CT, USA), was placed in PreservCyt (Cytyc Corp.,
Boxborough, MA, USA) and used to prepare a ThinPrep (Cytyc)
cytology slide and to perform the Hybrid Capture 2 (HC2, Digene
Corp., Gaithersburg, MD, USA) test, which targets 13 oncogenic
HPV types. The second sample, collected with a Dacron swab, was
placed in Specimen Transport Medium (Digene), frozen, and later
used for HPV typing by a polymerase chain reaction (PCR)-based
assay.
Subjects were randomized to one of three management arms: (1)
Conservative Management consisting of colposcopy referral
for repeat cytology of a high-grade squamous intraepithelial
lesion (HSIL); (2) HPV triage, with colposcopy referral for a
positive HC2 test for oncogenic types (or repeat cytology of HSIL,
which added almost no referrals); and (3) Immediate Colposcopy.
Subjects who received histologic diagnoses at the Clinical
Centers of cervical intraepithelial neoplasia 2 or worse (CIN2þ)
were treated with loop electrical excision procedure (LEEP).
The follow-up protocol was identical for all women: repeat
cytology every 6 months for 2 years, with colposcopy referral
for Clinical Center cytology of HSIL. At the 24-month (exit)
visit, all data were unmasked and reviewed for every subject,
colposcopy was performed, and women with CIN2þ or persistent
ASCUS or LSIL diagnosed by the Clinical Center were offered
treatment with LEEP, permitting detection of histologic CIN2þ
that was undetected by cytology and colposcopy. All referral
community smears and enrollment ThinPreps, most follow-up
ThinPreps, and all histology specimens were reviewed by a
Pathology Quality Control (QC) Group to provide standardized
interpretations and added subject safety (Schiffman and Adrianza,
2000).
HPV testing
HC2 testing was performed as described elsewhere (Lorincz, 1996;
Castle et al, 2004). Briefly, a 4ml-aliquot of residual PreservCyt
remaining after preparation of the thin-layer slide was used for
HC2 testing and estimation of viral load when a single, targeted
HPV type was present. The probe set includes HPVs 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 and 68. Specimens in which the
chemiluminescence equaled or exceeded that of a reference
standard containing 1.0pgml
 1 of HPV 16 DNA (approximately
5000 copies) were considered positive. The content of HPV DNA in
specimens that tested positive (‘HPV load’) was determined as
relative light units (RLU), calculated as the ratio of the signal of the
specimen to that of the standard, which is linearly related to load
(Sherman et al, 2002).
We performed HPV typing on DNA extracted from
cells collected in specimen transport medium (Digene, Gaithersburg,
MD, USA) using a PCR-based assay employing L1 consensus
primers and PGMY09/11 amplification followed by reverse
line blot hybridization as described elsewhere (Gravitt et al,
2000; Peyton et al, 2001). Although this PCR method is not
necessarily more sensitive analytically than HC2 (Castle et al,
2004), we used the combination of PCR and HC2 results to
determine the number of individual HPV types associated with
HC2 positive specimens.
Analysis
Clinical center cytology reports (available for all ThinPreps) and
Pathology QC histology results (the reference standard for
outcomes) were used for all analyses. For most analyses, we
stratified these data in three periods, reflecting serum hormone
fluctuations during a normal 28-day cycle: (1) days 1–10 (‘early,’
the period associated with lowest serum hormone levels); (2) days
11–21 (‘mid-cycle,’ corresponding to peak serum oestrogen
levels); and (3) days 22–28 (‘late,’ associated with peak serum
progesterone levels). For ease of interpretation of odds ratios
(ORs), we selected the late period as the referent group, which
generally yielded ORs X1.0 for most comparisons.
Of 25300 potential cytologic examinations that could have been
performed in ALTS (five examinations of 5060 women), cytology
results with associated LMP data in the range of 0–28 days were
available for 15389 interpretations. Missed visits (n¼4098),
failure to collect cytology specimens (n¼16) and LMPs greater
than day 28 day (n¼5797) accounted for the exclusions. HC2 data
were available for 14490 of these visits.
We used general estimating equations (GEE) to take into
account possible intra-individual ‘dependencies’ or ‘auto-correla-
tion’ (SAS Version 9.0, Cary, NC, USA) because many women
contributed multiple data points to the analysis (mean 3.4, s.d.
1.4). This approach provides an estimate of whether data from
individual women are correlated; strong auto-correlation reduces
the precision gains achieved for larger sample sizes, resulting in
reduced statistical power. We present ORs with 95% confidence
intervals (CI) using GEE models, although auto-correlation was
generally weak and adjustment widened CI only slightly.
We assessed specimen quality by LMP by tabulating the
frequency of reports of Bethesda System categories of ‘satisfactory
for interpretation’ or ‘unsatisfactory’ (Solomon, 1991). Next, for
satisfactory specimens, we examined the specific cytologic
interpretations (Negative for Intraepithelial Lesion or Malignancy
(NILM or Negative); ASCUS; LSIL, and High-grade Squamous
Intraepithelial Lesion or worse (HSILþ)) by time since LMP for
all women throughout the trial.
To consider how cytologic interpretations related to the most
severe histologic diagnosis per woman during the entire trial, we
stratified the cytologic results by whether or not a woman ever
received a histologic diagnosis of CIN2þ. Previous work within
ALTS showed that subsequent risk of CIN2þ or CIN3þ was
similar for women with a colposcopically-directed biopsy result of
CIN1, a negative biopsy, or a normal colposcopic appearance,
which did not prompt a biopsy (The ASCUS-LSIL Triage Study
(ALTS) Group, 2003). We only considered cytologic interpreta-
tions that were given before the histologic diagnosis of CIN2þ
that led to treatment, including the cytology result that prompted
colposcopy referral (number of cytology results ranged from 1 to
5). Clinical center cytologic interpretations were grouped at three
levels of cytologic abnormality (abnormal¼ASCUS, LSIL, or
HSILþ; abnormal¼LSILþ; and abnormal¼HSILþ). Taking
into account auto-correlation by GEE modeling, we assessed
whether LMP (three strata) affected the chance of an abnormal
cytology result among women with prevalent or incipient CIN2þ
as diagnosed by the Pathology QC group. We performed ancillary
analyses in which we excluded data from the Conservative
Management arm (which was insensitive) and in which we
restricted subjects to women with histologic CIN3þ.
To determine whether HC2 results varied by LMP, we assessed
the frequency of positive HC2 results varied by LMP, and then
repeated analyses specifically for ‘borderline HC2 results,’
previously defined as 0.8–1.5pgml
 1 (Federschneider et al,
2004). Previous analyses in ALTS have demonstrated that
infections with multiple oncogenic HPV types generally yield high
HPV load. However, in specimens containing multiple types, HC2
testing does not permit the assessment of the contribution that
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seach specific HPV type makes to the total load measure-
ment (Sherman et al, 2003). Therefore, we explored whether
the frequency of multiple infections (assessed by PCR) varied by
LMP.
Subsequent analyses regarding HPV results were restricted to
specimens with positive HC2 tests (pgml
 1X1.0) for which the
corresponding PCR test demonstrated only one of the 13
oncogenic types included in the HC2 kit. The specimens could
contain other types as well, not targeted by the assay. Of 3739
specimens that tested positive for only one of the 13 types by PCR
and which were associated with suitable LMP dates, there were
3004 specimens that tested positive by HC2 for which we assessed
viral load. To confirm the conclusions from this approach, we
analyzed associations between LMP data and viral load o1.0
(which are considered negative for clinical purposes but may
reflect rare HPV copies), and also analyzed LMP associations for
specimens containing any single HPV type, including types that
are not targeted by the HC2 kit. These analyses were confirmatory
and are not presented.
We performed ancillary analyses for single infections with HPV
16 or 18, the genotypes that account for the majority of cervical
cancer cases worldwide. Finally, we explored covariates such as
age, numbers of sexual partners, parity, oral contraceptive use, and
smoking, which were not informative and are not presented.
RESULTS
Frequency of cytology results and clinical performance by
last menstrual period
Unsatisfactory cytology results comprised 25 of 5384 (0.46%)
specimens collected early in the cycle, five of 6792
(0.07%) collected during mid-cycle, and eight of 3213 (0.25%)
collected late in the cycle. Considering specimens collected
late as the referent, the association with unsatisfactory specimens
yielded an OR¼1.87 (95% CI¼0.88–4.43) for the early period
and OR¼0.30 (95% CI¼0.09–0.89) for mid-cycle collections.
Unsatisfactory reports were most common on days 0–4
(data not shown). Intra-individual correlation was minimal
( 0.0019).
Among the 15351 satisfactory specimens that comprised the
rest of the analysis, the reported frequency of cytologic
interpretations in ALTS varied significantly by LMP, although
the magnitudes of absolute differences were slight (Table 1A). For
example, ASCUSþ cytologic interpretations were associated with
an OR¼1.12 (95% CI¼1.02–1.22) during the early period and an
OR¼1.10 (95% CI¼1.01–1.20) during mid-cycle, compared with
the late period. A minimally elevated percentage of LSILþ
(vspASCUS) was found for mid-cycle specimens (OR¼1.14,
95% CI¼1.03–1.28) compared with the late period. Reports of
HSIL declined progressively in frequency from early to late in the
cycle, yielding an OR¼1.38 (95% CI¼1.10–1.75) for the early
period and an OR¼1.20 (95% CI¼0.96–1.51) for mid-cycle. Of
note, at any level of severity, the intra-individual correlation of
cytologic interpretations for multiple specimens per woman was
weak (o0.25).
To explore the possible clinical relevance of the variation in
cytology by time since LMP, we restricted the study population to
women who received a histologic diagnosis of CIN2þ in ALTS
(Table 1B). Among these women with prevalent or incipient
histologic CIN2þ, cytology of ASCUSþ during the three LMP
intervals ranged from 82.4% (early cycle) to 79.8% (mid-cycle) to
82.8% (late cycle). The corresponding ORs were nonsignificant.
Similarly, we did not find substantial heterogeneity for cytology of
LSILþ (vs ASCUS or negative) or HSILþ (vs LSIL or less severe).
Analyses limited to women diagnosed with histologic CIN3þ, and
those restricted to the HPV- and IC-Arms ALTS yielded similar
results (data not shown).
HPV testing results stratified by last menstrual period and
other factors
We compared the frequency of HPV DNA positive test results by
HC2 for the three intervals of the menstrual cycle, without
restrictions. The auto-correlation estimate was 0.39, showing a
slight tendency of women that were HPV positive once to be
positive repeatedly. This strength of correlation was typical of all
HPV analyses, whether assessed as negative vs positive or as viral
load.
Overall, 44.6% of specimens were HC2 positive. Frequencies of
HC2 positive results were unrelated to the date of LMP. When we
assessed viral load among all HC2-positive tests (n¼6468
associated with one or multiple types by PCR), we obtained
slightly significant associations. Compared to specimens collected
late in the cycle, specimens obtained early in the cycle had viral
loads that were only 83% (95% CI¼0.71–0.98) as high, whereas
mid-cycle specimens yielded average loads that were 22% higher
(95% CI¼1.05–1.43).
The frequency of ‘borderline’ positive HC2 results varied only
slightly by date of LMP: 4.4% early in the cycle, 3.8% mid-cycle,
and 3.9% late in the cycle. These differences were not significantly
different.
Overall, positive HC2 test results and high viral loads are more
common for specimens containing multiple HPV types. Therefore,
we separately assessed the influence of LMP on load per type and
on the detection of multiple types. Date of LMP was not associated
with detection of multiple types by PCR (data not shown).
To study the associations between HPV viral load per type and
time of LMP, independent of number of HPV types present, we
assessed the frequency of positive HC2 results among specimens
associated with PCR detection of one of the 13 carcinogenic types
targeted by HC2. Positive HC 2 results were obtained for 1094 of
1377 (79.4%) specimens collected early in the cycle, 1315 of 1614
(81.5%) obtained at mid-cycle, and 595 of 748 (79.6%) late cycle
specimens (Table 2). Compared with specimens collected late in
the cycle, the ORs for HC2 positive tests were 0.99 (95% CI¼0.80–
1.24) early in the cycle and 1.13 (95% CI¼0.91–1.40) mid-cycle,
demonstrating a lack of a statistically significant association.
However, among HC2 positive specimens (RLUX1.0) contain-
ing only one of the 13 types, HPV load (overall mean
pgml
 1¼403.1, median 93.6) peaked at mid-cycle (Figure 1 and
Table 2). The general pattern of HPV load was a gradual increase
Table 1A Frequency (%) of cytologic interpretations stratified by last
menstrual period (LMP)
All cytologic results during 2-year period of trial
LMP – days Negative ASCUS LSIL HSIL+
0–10 (n¼5359) 3008 (56.1) 1373 (25.6) 734 (13.7) 244 (4.6)
11–21 (n¼6787) 3839 (56.6) 1597 (23.5) 1081 (15.9) 270 (4.0)
22–28 (n¼3205) 1886 (58.9) 747 (23.3) 465 (14.5) 107 (3.3)
Table 1B Frequency (%) of cytologic interpretations stratified by last
menstrual period (LMP), among women diagnosed with CIN2+
All cytologic results during 2-year period preceding
CIN2+
LMP – days Negative ASCUS LSIL HSIL+
0–10 (n¼499) 88 (17.6) 145 (29.1) 130 (26.1) 136 (27.3)
11–21 (n¼618) 125 (20.2) 140 (22.7) 201 (32.5) 152 (24.6)
22–28 (n¼308) 53 (17.2) 76 (24.7) 107 (34.7) 72 (23.4)
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sfrom days 3 to 4 to reach a plateau at mid-cycle, followed by a
decline in the late luteal phase. Among samples containing a single
type based on the PCR assay, those collected at mid-cycle
demonstrated 42% higher viral loads by HC2 (95% CI¼1.14–
1.77) than those collected late in the cycle. Tests performed on
specimens collected between days 0–2 and days 27–28 demon-
strated higher values than specimens obtained during flanking
intervals.
Joint consideration of cytology and HPV test results by
LMP
Increased viral load and cytologic abnormality were tightly linked,
making it impossible to determine which component was more
strongly associated with LMP. As shown in Table 2, mid-cycle
specimens showing SIL (with one of the 13 types) had a viral load
that was 38% higher on average (95% CI¼1.03–1.83) compared
with those collected late in the cycle. The increase in viral load was
weaker for ASCUS, and lacking when cytology was Negative.
Among HC2 positive specimens, the ratio of LSIL to ASCUS was
highest at mid-cycle, either as a cause or result of higher viral load.
The frequency of HPV-negative ASCUSþ (mainly ASCUS because
HPV-negative SIL is rare) did not vary by time of menstrual cycle
(data not shown). In sum, at mid-cycle viral load was higher when
cytology was abnormal, and cytology looked more definitively
abnormal when specimens were HPV-positive (Table 3)
Finally, we analysed data for single infections with HPV16
(n¼468 infected specimens) and HPV18 (n¼192) separately.
Among specimens collected early in the cycle that were associated
with concurrent single infections with HPV 16 (determined by
PCR), 77.7% of HC2 tests were positive, which was less sensitive
than HC2 tests performed on specimens collected late in the
menstrual cycle (OR¼0.52, 95% CI¼0.26–0.98). Viral load was
nonsignificantly lower (21.9%) for the specimens collected early as
opposed to late in the cycle. For mid-cycle specimens associated
with HPV 16, the frequency of HC2 positive results and load
determinations did not differ significantly from those obtained for
specimens late in the cycle. Among specimens associated with
concurrent detection of single infections with HPV 18 (detected by
PCR), positive HC2 results were more frequent at mid-cycle
(OR¼2.83, 95% CI¼1.09–7.39) and load was 55% higher (though
non-significantly) compared to specimens collected late in the
cycle.
DISCUSSION
This study demonstrates that the performance of thin-layer
cytology and HPV testing varies during the menstrual cycle,
although the fluctuations are modest. Cervical specimens collected
at mid-cycle (days 11–21) are probably optimal for detection
of HPV DNA by HC2 testing and for identification of LSIL by
thin-layer cytology. However, the effects of the date of LMP on
the performance of cytology and HC2 testing among women
diagnosed with histologic CIN2þ was minor, suggesting that it is
unnecessary to defer testing for women who present outside this
interval.
Ideally, optimizing the timing of specimen collection would
minimize unsatisfactory specimens and cytologic reporting of
ASCUS (now called ASC) overall and maximize clear-cut results of
SIL among women with underlying CIN2þ. Similar to results
obtained with conventional smears, specimens obtained early in
Table 2 Positive HC tests and HPV load by last menstrual period (LMP), overall and stratified by cytology
HC2 positive results among women with single
infections
a
Viral load of HC2 positive specimens, associated with single
infections
a
% HC2+
0–10 days
OR (95%CI)
11–21 days
OR (95%CI)
22–28
days
Mean
pg/ml
Median
pg/ml
0–10 days OR
(95%CI)
11–21 days
OR (95%CI)
22–28
days
All samples
(n¼3739)
80.3 0.99 (0.80–1.24) 1.13 (0.91–1.40) 1 (ref) 403.11 93.62 0.96 (0.76–1.20) 1.42 (1.14–1.77) 1 (ref)
SIL (n¼1186) 96.8 0.83 (0.31–1.97) 1.24 (0.47–2.98) 1 (ref) 721.0 533.86 0.90 (0.67–1.22) 1.38 (1.03–1.83) 1 (ref)
ASCUS (n¼981) 85.4 1.23 (0.76–1.98) 1.18 (0.73–1.87) 1 (ref) 323.4 75.07 0.84 (0.56–1.26) 1.16 (0.78–1.74) 1 (ref)
Negative (n¼1566) 64.8 0.87 (0.65–1.15) 0.93 (0.70–1.22) 1 (ref) 110.6 14.89 0.97 (0.70–1.33) 1.01 (0.74–1.38) 1 (ref)
aOne of 13 types of carcinogenic HPV targeted by HC2, as detected by PCR; cytology interpretations were unsatisfactory for six samples. Statistically significant values in bold.
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Figure 1 Human papillomavirus load vs days since last menstrual period
in 2-day intervals for all Hybrid Capture 2 positive results (pgml
 1X1.0).
The analysis is restricted to specimens associated with only one of the 13
carcinogenic types targeted by HC2, as determined by a PCR-based assay
performed on a second concurrently collected specimen.
Table 3 Frequency (%) of enrollment cytologic interpretations stratified
by last menstrual period (LMP), among HC2-positive specimens associated
with only one of 13 carcinogenic types targeted by HC2
a
LMP – days Negative ASCUS LSIL HSIL+
0–10 (n¼1093) 374 (34.2) 326 (29.8) 289 (26.4) 104 (9.5)
11–21 (n¼1318) 417 (31.6) 352 (26.7) 420 (31.9) 129 (9.8)
22–28 (n¼594) 225 (37.9) 162 (27.3) 158 (26.6) 49 (8.3)
aOnly one of the HPV types targeted by HC2 as detected by PCR, regardless of
other types present.
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sthe menstrual cycle were associated with the highest frequency of
unsatisfactory samples (Vooijs et al, 1987). Although addition of
glacial acetic acid to bloody cervical specimens may reduce the
frequency of unsatisfactory thin-layer slides, data suggest that this
treatment may cause false positive HC2 results, thus limiting the
subsequent utility of such specimens (Agoff et al, 2002).
Specimens collected early in the cycle yielded the high frequency
of HSIL cytology overall and among women who were diagnosed
with histologic CIN2þ, which could reflect improved sensitivity of
these samples compared to those obtained at other times in the
cycle. However, it is notable that reporting of HSILþ cytology was
also highest early in the cycle among women who were not
diagnosed with histologic CIN2þ. In addition, HPV negative test
results associated with HSILþ cytology were slightly higher early
in the cycle (7.3%) as compared to mid-cycle (4.4%) and late in the
cycle (2.9%), although these differences were not significantly
significant based on limited data. To account for these findings, we
speculate that misclassification of endometrial cells as HSIL
contributes to higher reporting of HSIL during the early part of
the cycle. In support of this hypothesis: (1) endometrial cells are
generally identified only during the first 10 days of the cycle; (2)
endometrial cells may mimic HSIL because of their similar small
size and high nuclear to cytoplasmic ratio, especially in liquid-
based cytology; and (3) the inconspicuousness of blood in most
thin-layer slides disguises the occurrence of menses. Previous
studies have emphasized that interpretation of HSIL in thin-layer
cytology may pose difficulties, especially with regard to false
negative results (Wilbur et al, 1996; Renshaw et al, 2004). Given
that both false negative and false positive interpretations of HSIL
may have undesirable consequences, efforts to improve the
recognition of HSIL are warranted.
Published data related to whether HPV detection varies with
time since LMP are inconclusive. In this analysis, the frequency of
positive HC2 results varied little by date of LMP. In a study based
on PCR testing of tampon specimens, HPV detection was also
unrelated to quartiles of the menstrual cycle (Fairley et al, 1994).
Two studies in which subjects were repeatedly tested using PCR
based assays found null associations between HPV detection and
LMP; however, these reports conflicted about whether recent
intercourse was associated with positive test results (Wheeler et al,
1996; Harper et al, 2003). Other reports based on repeated testing
have found associations between HPV detection and LMP. One
study demonstrated increased detection of HPV 16 during the
luteal phase (Schneider et al, 1992) and another identified HPV
more often between days 7 and 11 of the menstrual cycle (Van
Ham et al, 2002). Although the relationship between HPV
detection and LMP remains unclear, studies have consistently
found that point prevalence dramatically under-estimates cumu-
lative prevalence, indicating that low load infections are missed
with one-time testing.
Although the frequency of positive HC2 results among women
with a single carcinogenic infection was not associated with time
since LMP, we did find that HPV load among positive specimens
was modestly increased at mid-cycle, particularly among women
with cytology of SIL. These data are consistent with the increase in
abnormal cytology, particularly LSIL, at mid-cycle. The strong
correlation between cytology and load precludes a clear determi-
nation of whether the main effect of LMP is to increase HPV load
or evoke more abnormal cytology interpretations. Given either
interpretation, these findings suggest that adjusting for time since
LMP or collecting samples within the same phase of the cycle may
improve the interpretation of trends in viral load based on
repeated testing. Although HPV load measurements are too
variable to be used routinely for clinical management (Sherman
et al, 2002, 2003) data are conflicting about whether determining
HPV 16 load has value in identifying women at elevated risk for
developing cervical neoplasia in later follow-up (Josefsson et al,
2000; Lorincz et al, 2002). It is interesting that HC2 results were
less likely to be positive early in the cycle for women infected with
HPV 16 and that women with HPV 18 infections were more likely
to test HC2 positive at mid-cycle, although the underlying reasons
are unknown.
The mechanisms that result in measurement of higher
HPV loads at mid-cycle are obscure. We hypothesize that the
peak oestrogen levels at mid-cycle promote this effect by
reducing cellular adhesion, or by enhancing HPV viral replication,
suppressing local immunity or other alterations. In both
animal models and humans, oestrogen promotes epithelial
hyperplasia, metaplasia, and maturation of cervical epithelium,
creating a microenvironment suitable for HPV replication (Arbeit
et al, 1996; Elson et al, 2000). In HPV 16 transgenic mice, estrogen
treatment is required for carcinogenesis (Elson et al, 2000; Brake
and Lambert, 2005). In cell cultures, oestrogen interacts with
adhesion molecules, producing increased deformability and
contraction, which theoretically could facilitate cellular exfoliation
(Gorodeski, 1998). Finally, levels of immunoglobulins in cervical
secretions reach their nadir at mid-cycle, which may favour HPV
replication and accumulation to high viral loads (Franklin and
Kutteh, 1999; Nardelli-Haefliger et al, 2003). The explanation for
the observed, more minor spike in viral load around the time of
menses is also unexplained, although apoptosis secondary to
oestrogen withdrawal represents a possible explanation (Wang
et al, 2004).
Although this analysis was based on a clinical trial of over 5000
women who were followed with repeated examinations for 2 years,
we recognize some limitations. The majority of women in this
study were young and eligibility criteria included a recent cytology
report of ASCUS or LSIL, therefore, these results may not apply to
all women. In addition, the measurement of HPV load in cervical
cellular collections using HC2 does not necessarily reflect the
concentration of the virus in cervical tissue. In fact, it is recognized
that HC2 pgml
 1 values o1.0 may represent low levels of
infection; the analytical cutpoint for HC2 assays was selected to
optimize clinical sensitivity (i.e. disease detection) rather than
analytical sensitivity (detection of the lowest number of copies
possible). Finally, some collections that yielded positive PCR and
negative HC2 tests could reflect errors in HPV typing, differences
in HPV content between samples tested by HC2 and PCR or other
factors.
In conclusion, the LMP date is not a critical clinical considera-
tion if women with cytology of ASCUSþ are closely monitored
and HPV test results are categorized as negative or positive for
management. However, it is prudent when possible to schedule
screening tests at mid-cycle to optimize sensitivity and limit the
occurrence of unsatisfactory cytology. Standardized timing of
specimen collections may also minimize the inherent variability of
test results for individual patients, thereby facilitating interpreta-
tion of serial results. Improved understanding of the interactions
between hormones and HPV may eventually provide clues that are
useful for cancer prevention.
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